Claude Wischik

Professor Claude Wischik is a Clinical Professor at the University of Aberdeen, holding the Chair in Mental Health within the School of Medicine, Medical Sciences and Nutrition. His research focuses on the molecular neuropathology of Alzheimer's disease, particularly targeting tau protein pathology. He is affiliated with the Institute of Medical Sciences and has strong ties to TauRx Therapeutics Ltd, where his office is based. His work spans drug development (e.g., hydromethylthionine), biomarker strategies, and translational neuroscience. Key areas include tau aggregation inhibition, neuroinflammation, and clinical trial methodologies. His publications highlight contributions to Alzheimer's therapeutics, synucleinopathies, and neuropharmacology. While no awards are listed, his extensive patent portfolio and clinical trial involvement underscore his impactful research.

Research interests emphasize tau protein mechanisms, drug interactions (e.g., rivastigmine interference), and diagnostic tools like high-affinity tau antibodies. His studies leverage transgenic mouse models to explore synaptic dysfunction, cholinergic neuron protection, and motor deficiencies. Collaborations with institutions worldwide reflect his global influence in neurodegenerative research. Future work likely continues in tau-based therapies and personalized medicine for Alzheimer's.